Merck
HomeWebinarsDeveloping a Scalable Upstream Bioreactor Process for Lentiviral Vector Production in Suspension

Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Production in Suspension



WEBINAR

As gene therapy progresses toward broader clinical and commercial success, the industry is shifting from treating rare conditions to those of larger populations. This requires scalable solutions for process intensification. In this webinar, we discuss scale-up development for a common viral vector in gene therapy, lentivirus, using the VirusExpress™ Lentiviral Production Platform in Mobius® single-use bioreactors. We highlight critical considerations when moving from bench-scale to clinical scale process design with manufacturability in mind to ensure commercial readiness. Finally, we’ll review the significant benefits of implementing a templated manufacturing process.

In this webinar, you will learn:

  • Scale-up development of a suspension-based lentivirus production process
  • Designing a process that is manufacturing-friendly and supports commercialization
  • The benefits of having a templated manufacturing process

Speaker

Eva Fong

Eva Fong

Merck

Senior Scientist , Virus & Gene Therapy Bioprocessing

Eva received her B.S. in chemistry and biological sciences from the University of California, Irvine. Since graduating, she has held roles in multiple organizations, conducting pre-clinical, process development, engineering, and manufacturing activities for monoclonal antibody and viral vector therapeutics. Within Merck, she leads a team responsible for all upstream and downstream scale-up R&D to develop best-in-class lentiviral and AAV manufacturing products and templates.

Webinar Information

Pharma and biopharma manufacturing

  • Duration:42m

  • Language:English

  • Presented:Thu, February 25, 2021

    Watch Now